KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Cash from Investing Activities readings, the most recent being -$25.5 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 122.45% to -$25.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $297.0 million through Mar 2026, up 360.14% year-over-year, with the annual reading at $436.3 million for FY2025, 473.44% up from the prior year.
  • Cash from Investing Activities hit -$25.5 million in Q1 2026 for Alnylam Pharmaceuticals, up from -$37.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $501.1 million in Q3 2025 and bottomed at -$240.7 million in Q4 2023.
  • Average Cash from Investing Activities over 5 years is $7.5 million, with a median of -$30.2 million recorded in 2024.
  • Peak annual rise in Cash from Investing Activities hit 1756.55% in 2025, while the deepest fall reached 516.56% in 2025.
  • Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$139.9 million in 2022, then plummeted by 72.01% to -$240.7 million in 2023, then surged by 78.01% to -$52.9 million in 2024, then rose by 29.76% to -$37.2 million in 2025, then soared by 31.28% to -$25.5 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Cash from Investing Activities are -$25.5 million (Q1 2026), -$37.2 million (Q4 2025), and $501.1 million (Q3 2025).